AstraZeneca has entered into an agreement with Covis Pharma to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated
Fervent Pharmaceuticals has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for FP-101, its proprietary lead drug candidate for treating menopause symptoms, especially hot flashes.